6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
2019
This article is available under the terms of the Creative Commons Attribution License (CC BY).
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
36
References
108
Citations
NaN
KQI